文献速递免疫规划传染病防控与疫情报告

研究性MenABCWY疫苗在美国青少年中对110株侵袭性分离株的覆盖广度、免疫原性与安全性:一项随机对照观察者盲法II期研究

Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study.
PubMed 文献 · Vaccine · 2018-07-27

在美国8个中心开展的观察者盲法II期研究(NCT02140762及扩展NCT02285777)中,10-18岁青少年按1:1随机接受3剂MenABCWY(0、2、6月)或对照(第2月单剂MenACWY-CRM,0、6月安慰剂)。接种后1个月,2剂和3剂MenABCWY对110株B群侵袭株的覆盖广度分别为67%(95%CI: 65-69)和71%(95%CI: 69-73);至4个月分别降至44%(95%CI: 41-47)和51%(95%CI: 48-55)。2剂或3剂方案覆盖广度相似,各血清群抗原特异性试验株免疫应答稳健,未发现安全性担忧。

要点

  • 接种后1个月,2剂MenABCWY对110株B群侵袭株覆盖广度为67%(95%CI: 65-69),3剂为71%(95%CI: 69-73)。
  • 接种后4个月,覆盖广度在2剂后降至44%(95%CI: 41-47),3剂后降至51%(95%CI: 48-55)。
  • MenABCWY组各时间点对每个血清群抗原特异性试验株均观察到稳健免疫应答,研究期间无反应原性或安全性担忧。

核心结论

  • 2剂或3剂MenABCWY对美国B群侵袭性分离株面板显示相似的覆盖广度,对抗原特异性试验株免疫原性相当,未发现安全性担忧。

研究设计与样本

  • 在美国8个中心开展的观察者盲法II期研究(NCT02140762)及其扩展研究(NCT02285777)。
  • 10-18岁青少年按1:1随机分为MenABCWY组(0、2、6月接种3剂)和对照组(第2月单剂MenACWY-CRM,0、6月安慰剂)。
  • 母研究301名、扩展研究189名青少年接种疫苗。
  • 采用内源性补体血清杀菌试验,以(1-相对危险度)×100计算覆盖广度,相对危险度为MenABCWY组与对照组对所选菌株1:4稀释血清阴性样本百分比的比值。

主要发现

  • 接种后1个月,2剂MenABCWY对110株B群侵袭株覆盖广度为67%(95%CI: 65-69),3剂为71%(95%CI: 69-73)。
  • 接种后4个月,覆盖广度在2剂后降至44%(95%CI: 41-47),3剂后降至51%(95%CI: 48-55)。
  • MenABCWY组各时间点对每个血清群抗原特异性试验株均观察到稳健免疫应答。
  • 研究期间无反应原性或安全性担忧。

关键数值与推荐

  • 覆盖广度计算公式:(1-相对危险度)×100,相对危险度为MenABCWY组与对照组对所选菌株1:4稀释血清阴性样本百分比的比值。
  • 接种后1个月覆盖广度:2剂67%(95%CI: 65-69),3剂71%(95%CI: 69-73)。
  • 接种后4个月覆盖广度:2剂44%(95%CI: 41-47),3剂51%(95%CI: 48-55)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neisseria meningitidis serogroups A, B, C, W and Y cause most meningococcal disease worldwide. An investigational MenABCWY vaccine combining serogroup B antigens and a meningococcal ACWY CRM197-glycoconjugate vaccine (MenACWY-CRM) could provide protection against all 5 serogroups. Complement mediated bactericidal activity induced by MenABCWY was tested against a panel of 110 randomly-selected serogroup B strains causing invasive disease in the US to evaluate the vaccine's breadth of coverage (BoC). METHODS: We conducted this observer-blind study (NCT02140762) and its extension (NCT02285777) in 8 centers in the US. Adolescents aged 10-18 years were randomized (1:1) to receive either 3 MenABCWY doses (MenABCWY group), on a 0, 2, 6-month (M) schedule or a single MenACWY-CRM dose at M2 and placebo at 0,6-M (Control group). MenABCWY BoC was calculated as (1 - relative risk) × 100 (relative risk = ratio between the percentage of samples seronegative at 1:4 dilution against the selected strains in the MenABCWY vs Control group). BoC was determined at 1 M and 4 M after 2 and 3 doses, using an endogenous complement serum bactericidal assay. Immunogenicity and safety were assessed. RESULTS: 301 and 189 adolescents were vaccinated in the parent and extension study, respectively. At 1 M post-vaccination, the BoC of MenABCWY across the 110 serogroup B strains was 67% (95%CI: 65-69) after 2 doses and 71% (95%CI: 69-73) after 3 doses. BoC decreased to 44% (95%CI: 41-47) and 51% (95%CI: 48-55) at 4 M after 2 and 3 MenABCWY doses, respectively. Robust immune responses to antigen-specific test strains for each serogroup were observed at all timepoints in the MenABCWY group. No reactogenicity or safety concerns arose during the study. CONCLUSION: Two or 3 doses of MenABCWY showed similar BoC against the panel of invasive US serogroup B isolates and comparable immunogenicity against the antigen-specific test strains, with no safety concerns identified.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Welsch JA, Senders S, Essink B, et al. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study. Vaccine. 2018. PMID: 30061029. doi:10.1016/j.vaccine.2018.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。